Title:
APPLICATION OF PEG INTERFERON AND PROTO-ONCOGENE PRODUCT TARGETING INHIBITOR IN SYNERGISTIC TREATMENT OF RENAL CARCINOMA
Document Type and Number:
WIPO Patent Application WO/2021/062960
Kind Code:
A1
Abstract:
An application of an PEG interferon and a proto-oncogene product targeted inhibitor in synergistic treatment of renal carcinoma. Specifically, provided is use of a combination of active components, the combination of active components comprising the PEG interferon and the proto-oncogene product targeted inhibitor, and the combination being used for preparing a pharmaceutical composition for synergistic treatment of renal carcinoma. The combination of active components can effectively and synergistically inhibit renal carcinoma, and can significantly reduce toxic and side effects, and thus can be widely applied to tumor targeted treatment.
More Like This:
Inventors:
YANG YUFENG (CN)
HE CHENG (CN)
LOU JUEREN (CN)
HE CHENG (CN)
LOU JUEREN (CN)
Application Number:
PCT/CN2019/130747
Publication Date:
April 08, 2021
Filing Date:
December 31, 2019
Export Citation:
Assignee:
SHANGHAI INST OF BIOLOGICAL PRODUCTS CO LTD (CN)
International Classes:
A61K38/21; A61K39/00; A61P35/00; C07K17/02
Foreign References:
| CN1634993A | 2005-07-06 | |||
| CN105007896A | 2015-10-28 | |||
| EP2789628A2 | 2014-10-15 | |||
| CN105246915A | 2016-01-13 | |||
| CN200410067652A | 2004-10-29 |
Other References:
SHI, JIUHUA: "Newsletter: Bevacizumab plus interferon alpha only treats metastatic renal cell carcinoma", INTERNATIONAL JOURNAL OF BIOLOGICALS, vol. 32, no. 6, 31 December 2009 (2009-12-31), pages 305, XP009527231, ISSN: 1673-4211, DOI: 10.3760/cma.j.issn.1673-4211.2009.06.005
YANG, YUFENG: "Preparation and Properties of PEGylated Recombinant Human Interferon α1b", CHINESE JOURNAL OF BIOLOGICALS, vol. 23, no. 6, 30 June 2010 (2010-06-30), pages 615 - 618, XP055797745, DOI: 10.13200/j.cjb.2010.06.60.yangyf.013
SAMBROOK: "Molecular Cloning: Laboratory Guide", 1989, COLD SPRING HARBOR LABORATORY PRESS
ELENA GARCIA-MARTINEZ: "Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy", ONCOIMMUNOLOGY, vol. 7, no. 6, 2018, pages 16
XIANG CHEN ET AL.: "Clinical research progress of immunotherapy for renal cancer", CHINESE JOURNAL OF UROLOGY, vol. 38, no. 9, 2017, pages 717 - 720
XUE-LIN, CAO: "Mechanism of interferon adverse reactions", BIOMEDICAL ENGINEERING AND CLINICAL MEDICINE, vol. 14, no. 4, 2010, pages 340 - 342
JUN GUO: "Advances in medical therapy of metastatic renal cancer", THE SECOND CHINESE CONGRESS OF MEDICAL ONCOLOGY, 2008, pages 33 - 36
BRIAN I. RINI: "Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206", JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 13, 2010, pages 2137 - 2143
KUI-TANG TONG: "Interferon a treatment of melanoma", THE 17TH NATIONAL ACADEMIC CONFERENCE ON INTERFERONS AND CYTOKINES, 2011, pages 2 - 6
P. MASCI: "Gene Modulatory Effects, Pharmacokinetics, and Clinical Tolerance of Interferon a-lb: A Second Member of the Interferon a Family", CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 81, no. 3, 2007, pages 354 - 361
T. K. EIGENTLER: "Adjuvant treatment with pegylated interferon a-2a versus low-dose interferon a-2a in patients with high risk melanoma: a randomized phase III DeCOG trial", ANNALS OF ONCOLOGY, vol. 27, 2016, pages 1625 - 1632
THOMAS M. H: "U.S. Food and Drug Administration Approval: Peginterferon-alfa-2b for the Adjuvant Treatment of Patients with Melanoma", THE ONCOLOGIST, vol. 17, 2012, pages 1323 - 1328
"NCCN Clinical Practice Guidelines in Oncology - Malignant Melanoma", 2018, pages: MS-20
See also references of EP 4043027A4
YANG, YUFENG: "Preparation and Properties of PEGylated Recombinant Human Interferon α1b", CHINESE JOURNAL OF BIOLOGICALS, vol. 23, no. 6, 30 June 2010 (2010-06-30), pages 615 - 618, XP055797745, DOI: 10.13200/j.cjb.2010.06.60.yangyf.013
SAMBROOK: "Molecular Cloning: Laboratory Guide", 1989, COLD SPRING HARBOR LABORATORY PRESS
ELENA GARCIA-MARTINEZ: "Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy", ONCOIMMUNOLOGY, vol. 7, no. 6, 2018, pages 16
XIANG CHEN ET AL.: "Clinical research progress of immunotherapy for renal cancer", CHINESE JOURNAL OF UROLOGY, vol. 38, no. 9, 2017, pages 717 - 720
XUE-LIN, CAO: "Mechanism of interferon adverse reactions", BIOMEDICAL ENGINEERING AND CLINICAL MEDICINE, vol. 14, no. 4, 2010, pages 340 - 342
JUN GUO: "Advances in medical therapy of metastatic renal cancer", THE SECOND CHINESE CONGRESS OF MEDICAL ONCOLOGY, 2008, pages 33 - 36
BRIAN I. RINI: "Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206", JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 13, 2010, pages 2137 - 2143
KUI-TANG TONG: "Interferon a treatment of melanoma", THE 17TH NATIONAL ACADEMIC CONFERENCE ON INTERFERONS AND CYTOKINES, 2011, pages 2 - 6
P. MASCI: "Gene Modulatory Effects, Pharmacokinetics, and Clinical Tolerance of Interferon a-lb: A Second Member of the Interferon a Family", CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 81, no. 3, 2007, pages 354 - 361
T. K. EIGENTLER: "Adjuvant treatment with pegylated interferon a-2a versus low-dose interferon a-2a in patients with high risk melanoma: a randomized phase III DeCOG trial", ANNALS OF ONCOLOGY, vol. 27, 2016, pages 1625 - 1632
THOMAS M. H: "U.S. Food and Drug Administration Approval: Peginterferon-alfa-2b for the Adjuvant Treatment of Patients with Melanoma", THE ONCOLOGIST, vol. 17, 2012, pages 1323 - 1328
"NCCN Clinical Practice Guidelines in Oncology - Malignant Melanoma", 2018, pages: MS-20
See also references of EP 4043027A4
Attorney, Agent or Firm:
XU & PARTNERS, LLC. (CN)
Download PDF: